Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539838 | 0.90 | DGAT1 (1.00) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL4498080 | 0.88 | DGAT1 (0.79) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL13755344 | 0.87 | DGAT1 (1.00) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL4247738 | 0.82 | MAPT (0.86) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL3536673 | 0.82 | DGAT1 (1.00) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL3546334 | 0.81 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3542215 | 0.81 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL4496447 | 0.81 | DGAT1 (0.74) | DGAT1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL3542035 | 0.80 | DGAT1 (0.83) | DGAT1MAPTCYP1A2CYP2C19 | |
| SCHEMBL3540824 | 0.80 | DGAT1 (0.79) | DGAT1MAPTSMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | claimed |
| EP-1893592-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | claimed |
| WO-2006134317-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | claimed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| EP-1893592-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134317-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | DGAT1 3/4885MAPT 2561/4885SMN1; SMN2 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.